

Shaughnessy No: 080803

Date Out of EAB: JUN 10 1988

TO: Robert J. Taylor/Cynthia Giles
Product Manager #25
Registration Division (TS-767C)

FROM: Emil Regelman
Environmental Chemistry Review Section #3
Exposure Assessment Branch
Hazard Evaluation Division (TS-769C)

R

THRU: Paul F. Schuda, Chief
Exposure Assessment Branch/HED (TS-769C)

Paul F. Schuda

Attached, please find the EAB review of:

Reg./File #: 100-529

Chemical Name: ATRAZINE

Type product: Herbicide

Product Name: AATRAEX^R NINE-O^R

Company Name: Ciba-Geigy

Purpose: Review of study submitted in response to Registration Standard

Date Received: 6/8/88

Action Code: 660

Date Completed: 6/9/88

EAB #(s): 80811

Monitoring study requested:

Total Reviewing Time: 0.3 day

Monitoring study volunteered:

Deferrals to: Ecological Effects Branch

Residue Chemistry Branch

Toxicology Branch



2017968


1. CHEMICAL:

Chemical name: 2-chloro-4-ethylamino-6-isopropylamino-s-triazine

Chemical Abstracts #: 1912-24-9

Common name: ATRAZINE

Structure:



Physical state: powder

Color: white

Odor: odorless

Melting point: 175-177°C

Boiling point: not applicable

Vapor pressure: 3.0×10^{-7} mmHg at 20°C

Density: 1.19 gcm⁻³ at 20°C

Solubility at 20°C:

Water.....	33 ppm
Chloroform.....	5.2%
Diethyl ether.....	1.3%
Ethyl acetate.....	1.8%
n-pentane.....	0.04%

2. TEST MATERIAL: N/A.

3. STUDY/ACTION TYPE: Review of data submitted in response to the ATRAZINE Registration Standard.

4. STUDY IDENTIFICATION:

- Rustum, A.M. 1988. Aerobic, aerobic/anaerobic, and sterile soil metabolism of ¹⁴C-ATRAZINE. Conducted by Hazleton Laboratories America, Inc., Madison, WI. Study completed on April 25, 1988. Laboratory Study No. HLA 6015-185. Submitted by Ciba-Geigy Corp., Greensboro, NC. EPA MRID No. 40629303.

5. REVIEWED BY:

Silvia C. Termes
Chemist, Review Section #3
OPP/HED/EAB

Signature: 

Date: June 9th, 1988

6. APPROVED BY:

Emil Regelman
Supervisory Chemist
Review Section #3
OPP/HED/EAB

Signature: 

Date: JUN 10 1988

7. CONCLUSIONS:

The submitted environmental fate study is being retained at EAB and will be reviewed as part of the EAB Science Chapter for ATRAZINE, which is scheduled for completion (as a FRSTR) on 10/18/88.

8. RECOMMENDATIONS:

No recommendations.

CIBA-GEIGY

Agricultural Division
CIBA-GEIGY Corporation
P.O. Box 18300
Greensboro, North Carolina 27419
Telephone 919 292 7100

May 13, 1988

Mr. Robert J. Taylor
Product Manager (25)
Registration Division (TS-767C)
Office of Pesticide Programs
U.S. Environmental Protection Agency
1921 Jefferson Davis Highway
Crystal Mall 2 - Room 245
Arlington, VA 22202

Dear Mr. Taylor:

SUBJECT: ADDITIONAL DATA FOR ATRAZINE REREGISTRATION
ATRAZINE TECHNICAL, EPA REG. NO. 100-529

Enclosed please find three copies each of four (4) data volumes which are being provided as a follow-up to our November 17, 1987 submission of data under the subject action. Included in this submission are the following:


1. Aerobic/anaerobic soil metabolism - Originally due on November 17, 1987, an extension was granted for this study until this time in a September 10, 1987 letter from the Agency. In the November 1987 submission, a status of this study was provided.
2. Historical control data for mouse oncogenicity study - In the Agency letter of March 22, 1988, specific information was requested relating to historical control data for the facility where this study was conducted. The enclosed information represents all the available information which meets the criteria spelled out in the Agency letter. This information is intended to supplement the mouse study.
3. Re-evaluation of pathology data for rat combined chronic feeding/oncogenicity study - This supplement contains a re-examination of the original slides from the pathology report from this study, conducted at American Biogenics Corporation. The purpose of the re-evaluation was to determine if there was any progression of tumors from benign to malignant in the rat study. This study was submitted to the Agency May 5, 1986 and has subsequently been reviewed and accepted by the Agency. There was a finding of mammary tumors in the study, reported by CIBA-GEIGY, and confirmed by the Agency. It is felt that the enclosed supplement is useful in drawing conclusions about tumor progression and the accuracy of the original tumor

Page 2

identification.

If there are any questions concerning matters contained within this submission, please do not hesitate to contact us.

Sincerely,


Thomas J. Parshley
Regulatory Specialist

Enclosures